Style | Citing Format |
---|---|
MLA | Tajmirriahi M, et al.. "The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study." Neurology Asia, vol. 27, no. 4, 2022, pp. 845-849. |
APA | Tajmirriahi M, Sarafi R, Khorvash F, Saadatnia M (2022). The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study. Neurology Asia, 27(4), 845-849. |
Chicago | Tajmirriahi M, Sarafi R, Khorvash F, Saadatnia M. "The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study." Neurology Asia 27, no. 4 (2022): 845-849. |
Harvard | Tajmirriahi M et al. (2022) 'The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study', Neurology Asia, 27(4), pp. 845-849. |
Vancouver | Tajmirriahi M, Sarafi R, Khorvash F, Saadatnia M. The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study. Neurology Asia. 2022;27(4):845-849. |
BibTex | @article{ author = {Tajmirriahi M and Sarafi R and Khorvash F and Saadatnia M}, title = {The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study}, journal = {Neurology Asia}, volume = {27}, number = {4}, pages = {845-849}, year = {2022} } |
RIS | TY - JOUR AU - Tajmirriahi M AU - Sarafi R AU - Khorvash F AU - Saadatnia M TI - The Effect of Rivaroxaban Vs Aspirin on Stroke Recurrence Among Patients With History of Cryptogenic Stroke and Left Atrial Cardiomyopathy: An Analytical Cross-Sectional Study JO - Neurology Asia VL - 27 IS - 4 SP - 845 EP - 849 PY - 2022 ER - |